Version 1
: Received: 16 August 2024 / Approved: 16 August 2024 / Online: 16 August 2024 (18:21:47 CEST)
How to cite:
Sacchetti, S.; Ferrante, D.; Giacomini, L.; Zanotti, V.; Bellia, M.; Patriarca, A.; Gaidano, G.; Dianzani, U.; Rolla, R. The Role of New Research Parameters of the BC 6800 Plus Analyzer in the Differential Diagnosis of Lymphoid Neoplasms. Preprints2024, 2024081254. https://doi.org/10.20944/preprints202408.1254.v1
Sacchetti, S.; Ferrante, D.; Giacomini, L.; Zanotti, V.; Bellia, M.; Patriarca, A.; Gaidano, G.; Dianzani, U.; Rolla, R. The Role of New Research Parameters of the BC 6800 Plus Analyzer in the Differential Diagnosis of Lymphoid Neoplasms. Preprints 2024, 2024081254. https://doi.org/10.20944/preprints202408.1254.v1
Sacchetti, S.; Ferrante, D.; Giacomini, L.; Zanotti, V.; Bellia, M.; Patriarca, A.; Gaidano, G.; Dianzani, U.; Rolla, R. The Role of New Research Parameters of the BC 6800 Plus Analyzer in the Differential Diagnosis of Lymphoid Neoplasms. Preprints2024, 2024081254. https://doi.org/10.20944/preprints202408.1254.v1
APA Style
Sacchetti, S., Ferrante, D., Giacomini, L., Zanotti, V., Bellia, M., Patriarca, A., Gaidano, G., Dianzani, U., & Rolla, R. (2024). The Role of New Research Parameters of the BC 6800 Plus Analyzer in the Differential Diagnosis of Lymphoid Neoplasms. Preprints. https://doi.org/10.20944/preprints202408.1254.v1
Chicago/Turabian Style
Sacchetti, S., U. Dianzani and R. Rolla. 2024 "The Role of New Research Parameters of the BC 6800 Plus Analyzer in the Differential Diagnosis of Lymphoid Neoplasms" Preprints. https://doi.org/10.20944/preprints202408.1254.v1
Abstract
Background/Objectives: The latest WHO classification underscores the importance of the complete blood count (CBC) and cell morphology assessment in diagnosing lymphoid neoplasms. This study evaluated the diagnostic role of Research Use Only (RUO) parameters from the BC-6800 Plus Mindray analyzer in differentiating cell chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and other lymphoproliferative disorders. Methods: CBCs were performed on 90 patients (66% male, median age 67 years) with pathological blood counts (ALL, n=14; CLL, n=47; other lymphoproliferative disorders, n=29) at Novara’s University Hospital. Univariable and multivariable logistic regression assessed the association of basic (WBC, Hb, RDW, NE#, LY#, MO#, PLT) and research cell parameters (NLR, NMR, LMR, NeuX, NeuY, NeuZ, LymX, LymY, LymZ, MonX, MonY, MonZ). Results: In multivariable analysis, Hb (p=0.02), NeuY (p=0.04), and MonY (p=0.01) independently predicted CLL versus ALL, correctly classifying 93.4% of cases (AUC 0.91, 95% CI 0.81-1.0). MO# (p=0.003), LymY (p<0.0001), and MonY (p=0.004) were independent predictors of CLL versus other lymphoproliferative disorders, classifying 77.6% of cases (AUC 0.86, 95% CI 0.78-0.95). NeuZ (p=0.01) and NeuY (p=0.04) independently predicted ALL versus other lymphoproliferative disorders, classifying 93% of cases (AUC 0.98, 95% CI 0.95-1.0). Conclusions: The use of RUO parameters offers valuable, cost-effective support in the early diagnosis of ALL, CLL, and other lymphoproliferative disorders.
Keywords
acute lymphoblastic leukemia; chronic lymphocytic leukemia; early diagnosis; leukocyte parameters; other lymphoproliferative disorders; morphological parameters
Subject
Biology and Life Sciences, Life Sciences
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
